RxDoctor Payments DataLook up a doctor →

Priti Manohar, MD

Neurology with Special Qualifications in Child Neurology · Edinburg, TXNPI 1336169945

Payments from drug & device makers

$13,136in general payments, 2019–2025

Across 613 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$3K
  • UCB, Inc.$2K
  • Neurelis, Inc.$732
  • Neurocrine Biosciences, Inc.$581
  • Cadwell Industries, Inc$550
  • Teva Pharmaceuticals USA, Inc.$452
  • plus $6K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.37$2,544
UCB, Inc.92$1,922
Neurelis, Inc.21$732
Neurocrine Biosciences, Inc.30$581
Cadwell Industries, Inc1$550
Teva Pharmaceuticals USA, Inc.30$452
Eisai Inc.44$428
Sunovion Pharmaceuticals Inc.69$405
Genentech USA, Inc.19$396
Biogen20$395
Acadia Pharmaceuticals Inc19$370
Upsher-smith Laboratories LLC18$319
Sumitomo Pharma America, Inc.35$305
Amgen13$297
Lilly USA, LLC12$274
Lundbeck LLC11$249
Biohaven Pharmaceutical Holding Company Ltd.15$225
Supernus Pharmaceuticals, Inc.10$207
Kyowa Kirin, Inc.7$184
Adamas Pharmaceuticals, Inc.10$177
Tris Pharma Inc2$173
Jazz Pharmaceuticals Inc.5$172
Pfizer8$145
Acorda Therapeutics, Inc6$130
Aquestive Therapeutics, Inc.7$124
Biohaven Pharmaceuticals, Inc.5$94
Zogenix Inc.5$91
PTC Therapeutics, Inc.4$86
Banner Life Sciences, LLC4$83
Catalyst Pharmaceuticals, Inc.4$82
AbbVie(2 entities)5$79
Sarepta Therapeutics, Inc.4$70
Shire North American Group Inc4$69
Takeda Pharmaceuticals U.S.A., Inc.3$66
Biomarin Pharmaceutical Inc.4$57
AstraZeneca3$56
Merz Pharmaceuticals, LLC2$55
Livanova USA, Inc.2$54
Ironshore Pharmaceuticals Inc.2$40
Immedica Pharma US, Inc.1$34
Vanda Pharmaceuticals Inc.1$33
Otsuka America Pharmaceutical, Inc.1$27
GE HealthCare1$26
Greenwich Biosciences, Inc.1$26
MDD US Operations, LLC2$26
Springworks Therapeutics, Inc.1$26
Biocodex, Inc.1$22
Novartis1$20
Mallinckrodt Hospital Products Inc.1$19
GRT US Holding, Inc.1$18
Arbor Pharmaceuticals, Inc.1$17
Aucta Pharmaceuticals, Inc.1$17
ITF Therapeutics LLC1$15
Johnson & Johnson1$14
Azurity Pharmaceuticals, Inc.1$13
Tanabe Pharma America, Inc.1$12
Avion Pharmaceuticals1$12
Metacel Pharmaceuticals LLC1$11
Corium, LLC1$8

How this compares

$13,136 in reported general payments places this provider in the 75th percentile of 193 neurology with special qualifications in child neurology providers in Texas.

See all neurology with special qualifications in child neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$68,037
Medicare patients
156
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in Edinburg

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →